Alacer Sale Underscores Value-Add Of Best Practices
This article was originally published in The Tan Sheet
Executive Summary
Best practices help establish a firm’s appeal as an acquisition target, illustrated by the case of Pfizer’s acquisition of Emergen-C maker Alacer.`
You may also be interested in...
Defend-Eeze Launches In US Zinc Cold Remedy Market
Vespyr, incorporated in December 2021 after operating as Nurya when it acquired Cold-Eeze from Mylan in May that year, offers Defend-Eeze in lozenges containing echinacea, elderberry and vitamins C and D3 in addition to zinc.
P&G Wraps Launch Of Super C Supplement Brand In Co-Packaging With DayQuil And NyQuil OTCs
P&G could be using a door left open in FDA’s 2015 proposed rule that questioned the safety of offering co-packaged supplements and drugs. With OTC drug and supplement firms always looking to drive sales growth, competitors large and small could follow P&G through the door.
GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line
UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.